Oryzon Secures U.S. Patent for Vafidemstat in Borderline Personality Disorder
Event summary
- U.S. Patent No. 12,673,044 granted for treating non-aggressive symptoms of BPD with vafidemstat.
- Patent expires in March 2043, including 1,095 days of Patent Term Adjustment.
- Corresponding Canadian patent application also received a Decision to Grant.
- Additional patents granted or allowed in Australia, Europe, Japan, Malaysia, Mexico, Russia, Singapore, and South Africa.
The big picture
Oryzon's U.S. patent grant for vafidemstat in BPD strengthens its intellectual property portfolio, supporting its lead CNS program. This move comes amid a broader industry trend of biopharmaceutical companies securing patents to protect their innovative treatments and attract investment. The company's focus on epigenetics and personalized medicine positions it well in the competitive landscape of neuropsychiatric disorder treatments.
What we're watching
- Patent Protection
- The extent to which the extended patent protection will safeguard Oryzon's market position in BPD treatments.
- Clinical Trials
- The progress of Phase III trials for aggression in BPD and upcoming Phase II trials in ASD and schizophrenia.
- Commercial Potential
- Whether the strengthened IP position will attract partners or investors to support vafidemstat's long-term development.